Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TYRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTyra Biosciences expands board to 10 members, appoints former Acceleron CEO Habib Dable
Filed April 17, 2026 · Period ending April 16, 2026 · ~1 min read
Key Changes
-
medium
Board expanded from nine to ten directors with appointment of Habib J. Dable as Class II director, term expiring at 2026 annual meeting. Dable previously led Acceleron Pharma through its acquisition by Merck in 2021.
Item 5.02 verify on EDGAR → -
medium
New director brings pharmaceutical industry expertise from leadership roles at Bayer and Acceleron, currently serves as advisor at RA Capital Management and on multiple biotech boards.
Item 5.02 verify on EDGAR → -
low
Dable granted options to purchase 44,400 shares at fair market value, vesting monthly over 36 months, plus standard non-employee director cash compensation.
Item 5.02 verify on EDGAR → -
low
Board determined Dable qualifies as independent director under Nasdaq listing requirements with no related party transactions affecting independence.
Item 5.02 verify on EDGAR →
Summary
Tyra Biosciences added pharmaceutical industry veteran Habib J. Dable to its board of directors, expanding the board from nine to ten members. Dable brings significant M&A and drug development experience, having served as CEO of Acceleron Pharma through its successful acquisition by Merck in 2021. He currently advises RA Capital Management and holds board positions at several biotechnology companies.
For retail investors, this appointment signals potential strategic direction as Tyra advances its pipeline of precision oncology therapies. Dable's track record in building and selling a successful biotech company could prove valuable if Tyra pursues partnerships or acquisition opportunities.
His experience navigating late-stage clinical development and commercialization may also benefit the company as its lead programs progress. Watch for Dable's committee assignments in future proxy filings, which will indicate where the board expects him to contribute most. His involvement in strategic planning discussions could become visible through future corporate development announcements or clinical trial expansions.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 16, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors (the Board) of Tyra Biosciences, Inc. (the Company), and pursuant to the amended and restated bylaws of the Company, the Board approved an increase in the number of authorized directors from nine to ten and appointed Habib J. Dable to the Board as a Class II director with an initial term expiring at the Company’s 2026 annual meeting of stockholders.
The company expanded its board from nine to ten directors and appointed Habib J. Dable as a new Class II director. Mr. Dable is an advisor at RA Capital Management and previously served as CEO of Acceleron Pharma until its acquisition by Merck in 2021. He brings extensive pharmaceutical industry experience from leadership roles at Bayer and currently serves on multiple biotech company boards.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
In connection with his appointment to the Board, pursuant to the Company’s Non-Employee Director Compensation Program, Mr. Dable was granted options to purchase 44,400 shares of the Company’s common stock. The options have an exercise price per share equal to the fair market value of the Company’s common stock on the date of grant. The foregoing awards will vest in substantially equal monthly installments over the thirty-six months following the date of grant.
Mr. Dable received stock options to purchase 44,400 shares at fair market value as part of his director compensation. These options vest monthly over three years. He will also receive standard cash compensation for board and committee service under the company's Non-Employee Director Compensation Program.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify